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In recent years, treatment methods on immune checkpoints have emerged 
as promising novel therapeutic modalities against cancer as a result of 
studies focusing on elucidation of immune micro-environment. Immuno-
therapy has now become an established treatment in some cancers. [1-2] 
This has led the need for investigation of biomarkers which allow deter-
mining effectiveness of immunotherapies and patient groups which will 
most benefit from these therapies. In previous studies, it was suggested 
that programmed death receptor-1 (PD-1) and programmed death ligand-1 
(PD-L1) expressions could be predictive biomarkers in cancers. PD-1 is a 
transmembrane protein present in macrophages, myeloid dendritic cells, 
B cells, epithelial cells and vascular endothelial cells, which limits and in-
hibits immunological activation in activated T cells. Blocking PD-1/PD-
L1 interaction promises hope in the cancer treatment.  In clinical studies, 
it was shown that targeted PD-1/PD-L1 therapy alone or in combination 
with other modalities is beneficial in advanced cancers with aggressive 
behavior. It was shown that overexpression of PD-1 present in tumoral 
micro-environment is associated to poor prognosis in gastric cancer, 
breast cancer, ovarian cancer, kidney, pancreas and lung cancers and in 
melanoma. [1-5]
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1. Introduction
Radiotherapy exerts its effect by enhancing death in irradiated tumor cells and elimination inflamma-tion at tumor micro-environment. In other words, 
it exerts its effect by inducing antigen expression on tu-
mor cells and activating lymphocytes. 1,2 Radiation can 
induce either inflammatory or anti-inflammatory reactions 
depending on dose and fractionation. In a study, Patel et 
al. assessed activated and enhancing T cell infiltration in 
high-dose (15-20 Gy;1-3 fractions) and low-dose (3-5 
Gy;4-5 fractions) radiotherapy regimens. Authors empha-
sized that T cell infiltration was higher resulting in delay 
in tumor growth in high-dose regimens. 4 Dewan et al. 
investigated different dose and schemes (20 Gy/one frac-
tion; 24 Gy/3 fractions; 30 Gy/5 fractions) on two poorly 
immunogenic tumors. Authors found that anti-tumor ac-
tivity was higher in those received 24 Gy in 3 fractions. [5] 
2. Study and Test
The success of blockade of PD-1/PD-L1 pathway 
in combination with radiotherapy in killing tumors in 
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preclinical studies has encouraged researchers for test-
ing these agents in some tumors. In preclinical studies, 
it was shown that concomitant use of immunotherapy 
with radiotherapy was more effective than sequential 
administration. Currently, phase 1 and 2 clinical trials 
investigating combination of targeted PD-1 and PD-L1 
blockage with chemotherapy (NCT02305186) and radio-
therapy (NCT02303990, NCT02311361, NCT02298946) 
are ongoing. In published series, controversial outcomes 
have been reported regarding timing of immunotherapy in 
accurate dose and fractionation of radiotherapy. Radiation 
necrosis is most common adverse effect of radiotherapy 
and immunotherapy, which is difficult to manage. 2,4 
3. Conclusion
In conclusion, programmed death pathway is an im-
portant immune control step that functions in late phases 
of inflammation. Targeted PD-1/PD-L1 therapy in com-
bination with radiotherapy may enable promising results 
in cancer patients. It is now unclear which radiotherapy 
technique or regiment will be effective together with im-
munotherapy. It seems very important to produce a syner-
gism between radiation dose and immune system. Further 
prospective, randomized studies with large sample size 
are needed for this purpose.  
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